Related Experiment Video
Updated: Jul 6, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
[The study on the tolerability of perindopril in patients with stable coronary heart disease]
1, Xiao-wei Yan
1Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. xswy_pumc@yahoo.com.cn
Insights
Perindopril 8 mg/d is well tolerated in Chinese patients with stable coronary heart disease (CHD). The dose adjustment from 4 mg/d to 8 mg/d showed significant blood pressure reduction in hypertensive patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Stable coronary heart disease (CHD) management often involves ACE inhibitors.
- Perindopril is a commonly prescribed angiotensin-converting enzyme inhibitor.
Purpose of the Study:
- To assess the tolerability of increasing perindopril dosage from 4 mg/d to 8 mg/d.
- To evaluate the safety and efficacy of perindopril dose escalation in Chinese patients with stable CHD.
Main Methods:
- Open-label, multicenter study involving 109 Chinese patients with stable CHD.
- Patients previously tolerated perindopril 4 mg/d for at least one month.
- Monitoring of adverse events, blood pressure, heart rate, and laboratory parameters (Na+, K+, Cr, BUN) at baseline and weeks 4 and 8.
Main Results:
- 16.5% of patients experienced mild adverse events; no serious adverse events were reported.
- Perindopril 8 mg/d was well tolerated by 93.6% of patients.
- Significant reduction in blood pressure observed in patients with elevated baseline blood pressure (P < 0.01).
Conclusions:
- Perindopril 8 mg/d is well tolerated in Chinese patients with stable coronary heart disease.
- Dose escalation to 8 mg/d is a safe and effective option for managing blood pressure in this population.
Objective:
To evaluate the tolerability of perindopril dose-adjustment from 4 mg/d to 8 mg/d in Chinese patients with stable coronary heart disease (CHD).
Methods:
CHD patients with or without hypertension were eligible to this open lebel, multicenter study. Before admission, all patients received and tolerated perindopril 4 mg/d for at least 1 month. Adverse events, blood pressure, heart rate, Na(+), K(+), Cr, BUN at baseline, week 4 and week 8 were recorded.
Results:
A total of 109 patients with stable CHD were included in this study, 18 out of 109 (16.5%) patients experienced mild adverse events during observation period. No serious adverse event was recorded. Perindopril 8 mg/d was well tolerated in 102 patients (93.6%). One patient (0.9%) withdrew from the study because of severe cough. In patients with elevated baseline blood pressure, switching perindopril from 4 mg/d to 8 mg/d significantly lowered blood pressure from (149.4 +/- 7.6)/(84.1 +/- 11.0) mm Hg (1 mm Hg = 0.133 kPa) to (128.8 +/- 14.2)/(79.5 +/- 8.9) mm Hg (P < 0.01). Serum electrolytes, creatinine and BUN were stable during study period.
Conclusion:
Perindopril 8 mg/d can be well tolerated by Chinese patients with stable coronary heart disease.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:22Heart Failure Drugs: β-Blockers
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:26Angina IV: Management